Anika Therapeutics, Inc. Excess Tax Benefit from Share-based Compensation, Financing Activities
Anika Therapeutics, Inc. (ANIK) reported Excess Tax Benefit from Share-based Compensation, Financing Activities of $647.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-24.
Discontinued › Notes › Compensation Related Costs
us-gaap:ExcessTaxBenefitFromShareBasedCompensationFinancingActivities · last filed 2017-02-24
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-12-31 was $226.00K.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-09-30 was $2.00K.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-06-30 was $55.00K.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for the quarter ending 2016-03-31 was $364.00K, a 61.03% decline year-over-year.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2016 was $647.00K, a 23.61% decline from fiscal 2015.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2015 was $847.00K, a 91.20% decline from fiscal 2014.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2014 was $9.63M, a 1023.22% increase from fiscal 2013.
- Anika Therapeutics, Inc. excess tax benefit from share-based compensation, financing activities for fiscal 2013 was $857.00K, a 89.40% increase from fiscal 2012.
| Period end | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 3 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 6 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 9 month as first filed | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month | Excess Tax Benefit from Share-based Compensation, Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2016-12-31 | $226.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $228.00K derived: sum of 2 quarters · filed 2017-02-24 | $283.00K derived: sum of 3 quarters · filed 2017-02-24 | $647.00K 10-K · filed 2017-02-24 | ||||
| 2016-09-30 | $2.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | $57.00K derived: sum of 2 quarters · filed 2016-11-01 | $421.00K 10-Q · filed 2016-11-01 | $391.00K derived: sum of 4 quarters · filed 2017-02-24 | ||||
| 2016-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $419.00K 10-Q · filed 2016-08-01 | $389.00K derived: sum of 3 quarters · filed 2017-02-24 | $332.00K derived: sum of 4 quarters · filed 2017-02-24 | ||||
| 2016-03-31 | $364.00K 10-Q · filed 2016-05-03 | $334.00K derived: sum of 2 quarters · filed 2017-02-24 | $277.00K derived: sum of 3 quarters · filed 2017-02-24 | $277.00K derived: sum of 4 quarters · filed 2017-02-24 | ||||
| 2015-12-31 | -$30.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | -$87.00K derived: sum of 2 quarters · filed 2017-02-24 | -$87.00K derived: sum of 3 quarters · filed 2017-02-24 | $847.00K 10-K · filed 2017-02-24 | ||||
| 2015-09-30 | -$57.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-01 | -$57.00K derived: sum of 2 quarters · filed 2016-11-01 | $877.00K 10-Q · filed 2016-11-01 | $876.80K 10-Q · filed 2015-11-03 | $1.27M derived: sum of 4 quarters · filed 2017-02-24 | |||
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-01 | $934.00K 10-Q · filed 2016-08-01 | $933.86K 10-Q · filed 2015-08-04 | $1.32M derived: sum of 3 quarters · filed 2017-02-24 | $1.25M derived: sum of 4 quarters · filed 2017-02-24 | |||
| 2015-03-31 | $934.00K 10-Q · filed 2016-05-03 | $933.86K 10-Q · filed 2015-05-04 | $1.32M derived: sum of 2 quarters · filed 2017-02-24 | $1.25M derived: sum of 3 quarters · filed 2017-02-24 | $6.12M derived: sum of 4 quarters · filed 2017-02-24 | |||
| 2014-12-31 | $389.29K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24 | $317.89K derived: sum of 2 quarters · filed 2017-02-24 | $5.19M derived: sum of 3 quarters · filed 2017-02-24 | $9.63M 10-K · filed 2017-02-24 | $9.63M 10-K · filed 2015-03-13 | |||
| 2014-09-30 | -$71.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-03 | $4.80M derived: sum of 2 quarters · filed 2015-11-03 | $9.24M 10-Q · filed 2015-11-03 | $9.33M derived: sum of 4 quarters · filed 2016-03-10 | ||||
| 2014-06-30 | $4.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-04 | $9.31M 10-Q · filed 2015-08-04 | $6.83M 10-Q · filed 2014-08-04 | $9.40M derived: sum of 3 quarters · filed 2016-03-10 | $10.16M derived: sum of 4 quarters · filed 2016-03-10 | |||
| 2014-03-31 | $4.44M 10-Q · filed 2015-05-04 | -$4.44M 10-Q · filed 2014-05-05 | $4.53M derived: sum of 2 quarters · filed 2016-03-10 | $5.29M derived: sum of 3 quarters · filed 2016-03-10 | $5.36M derived: sum of 4 quarters · filed 2016-03-10 | |||
| 2013-12-31 | $92.82K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10 | $849.40K derived: sum of 2 quarters · filed 2016-03-10 | $921.64K derived: sum of 3 quarters · filed 2016-03-10 | $857.00K 10-K · filed 2016-03-10 | -$856.83K 10-K · filed 2014-03-13 | |||
| 2013-09-30 | $756.59K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $828.82K derived: sum of 2 quarters · filed 2014-11-06 | $764.18K 10-Q · filed 2014-11-06 | -$764.18K 10-Q · filed 2013-11-05 | $1.67M derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2013-06-30 | $72.24K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $7.60K 10-Q · filed 2014-08-04 | $916.86K derived: sum of 3 quarters · filed 2015-03-13 | $59.74K derived: sum of 4 quarters · filed 2015-03-13 | ||||
| 2013-03-31 | -$64.64K 10-Q · filed 2014-05-05 | $64.64K 10-Q · filed 2013-05-06 | $844.63K derived: sum of 2 quarters · filed 2015-03-13 | -$12.50K derived: sum of 3 quarters · filed 2015-03-13 | -$6.25K derived: sum of 4 quarters · filed 2015-03-13 | |||
| 2012-12-31 | $909.27K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-13 | $52.15K derived: sum of 2 quarters · filed 2015-03-13 | $58.40K derived: sum of 3 quarters · filed 2015-03-13 | $452.47K 10-K · filed 2015-03-13 | ||||
| 2012-09-30 | -$857.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | -$850.87K derived: sum of 2 quarters · filed 2013-11-05 | -$456.80K 10-Q · filed 2013-11-05 | $456.80K 10-Q · filed 2012-11-08 | ||||
| 2012-06-30 | $6.25K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-06 | $400.32K 10-Q · filed 2013-08-06 | ||||||
| 2012-03-31 | $394.08K 10-Q · filed 2013-05-06 | |||||||
| 2011-12-31 | -$274.19K 10-K · filed 2014-03-13 | $274.19K 10-K · filed 2012-03-13 | ||||||
| 2010-12-31 | $65.43K 10-K · filed 2013-03-14 | |||||||
| 2009-12-31 | $27.35K 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |